Duncan D, Cooke L, Symonds C Quetiapine use in adults in the community: a population-based study in Alberta, Canada. BMJ Open. 2016; 6

Lin CY, Chiang CH, Tseng MM, Tam KW, Loh EW. Effects of quetiapine on sleep: A systematic review and meta-analysis of clinical trials. Eur Neuropsychopharmacol. 2023; 67:22-36

Lopes LPN, de Oliveira JC, Bergamaschi CDC Use of second-generation antipsychotics in autism spectrum disorder: a systematic review and meta-analysis protocol. BMJ Open. 2023; 13

Maneeton N, Maneeton B, Woottiluk P Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2016; 10:259-276

NHS. About quetiapine. 2022. https// (accessed 16 September 2023)

Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry. 2018; 17:(3)341-356

Evolution of the use of quetiapine

02 November 2023
Volume 5 · Issue 11

Quetiapine is a second-generation antipsychotic, primarily intended for use in people with schizophrenia, bipolar disorder type one or two, or as an adjunct for major depressive disorder (NHS, 2022). It has become increasingly popular off-label, however, for use on its own for anxiety, sleep disturbance, depression, and other disorders such as emotional dysregulation in personality disorders. Due to its changing use, it is important to look at recent research that may indicate its usefulness for a range of mental health concerns.

Duncan et al (2016) published a study in the BMJ Open, which evaluated trends in the prescribing of quetiapine to adults in the Canadian province of Alberta between 2008 and 2013. The authors examined dispensed prescriptions, and diagnoses associated with people who were using quetiapine in 2013 and analysed administrative data from Alberta Health, the Alberta Pharmaceutical Information Network (PIN) Dispenses health data set, the Practitioner Payments (Fee-For-Service claims) health data set and the Population Registry health data set. This meant that the team could identify any person using quetiapine for each year from 2008 to 2013. The diagnoses were then evaluated by examining for diagnostic codes used by doctors when filing billings claims in 2013.

Register now to continue reading

Thank you for visiting Journal of Prescribing Practice and reading some of our peer-reviewed resources for prescribing professionals. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to our clinical or professional articles

  • New content and clinical newsletter updates each month